Maintenance therapy in non-small-cell lung cancer

被引：12

作者：

Stinchcombe, Thomas E. ^{[1
]}

West, Howard L. ^{[2
]}

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[2] Swedish Canc Inst, Seattle, WA USA

来源：

LANCET | 2009年 / 374卷 / 9699期

关键词：

PHASE-III TRIAL; DOCETAXEL; CHEMOTHERAPY;

D O I：

10.1016/S0140-6736(09)61598-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1398 / 1400

页数：3

共 14 条

[1]

[Anonymous], 2009, COMM MED PROD HUM US

[2]

[Anonymous], 13 WORLD C LUNG CANC

[3] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].

Ciuleanu, Tudor ;

Brodowicz, Thomas ;

Zielinski, Christoph ;

Kim, Joo Hang ;

Krzakowski, Maciej ;

Laack, Eckart ;

Wu, Yi-Long ;

Bover, Isabel ;

Begbie, Stephen ;

Tzekova, Valentina ;

Cucevic, Branka ;

Pereira, Jose Rodrigues ;

Yang, Sung Hyun ;

Madhavan, Jayaprakash ;

Sugarman, Katherine P. ;

Peterson, Patrick ;

John, William J. ;

Krejcy, Kurt ;

Belani, Chandra P. .

LANCET, 2009, 374 (9699) :1432-1440

[4] Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up [J].

D'Addario, G. ;

Felip, E. .

ANNALS OF ONCOLOGY, 2009, 20 :68-70

[5]

European Medicines Agency (EMA), 2008, CHMP/EWP/18504/2006

[6] Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer [J].

Fidias, Panos M. ;

Dakhil, Shaker R. ;

Lyss, Alan P. ;

Loesch, David M. ;

Waterhouse, David M. ;

Bromund, Jane L. ;

Chen, Ruqin ;

Hristova-Kazmierski, Maria ;

Treat, Joseph ;

Obasaju, Coleman K. ;

Marciniak, Martin ;

Gill, John ;

Schiller, Joan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) :591-598

[7] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[8] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[9] Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial [J].

Kim, Edward S. ;

Hirsh, Vera ;

Mok, Tony ;

Socinski, Mark A. ;

Gervais, Radj ;

Wu, Yi-Long ;

Li, Long-Yun ;

Watkins, Claire L. ;

Sellers, Mark V. ;

Lowe, Elizabeth S. ;

Sun, Yan ;

Liao, Mei-Lin ;

Osterlind, Kell ;

Reck, Martin ;

Armour, Alison A. ;

Shepherd, Frances A. ;

Lippman, Scott M. ;

Douillard, Jean-Yves .

LANCET, 2008, 372 (9652) :1809-1818

[10] The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies [J].

Scagliotti, Giorgio ;

Hanna, Nasser ;

Fossella, Frank ;

Sugarman, Katherine ;

Blatter, Johannes ;

Peterson, Patrick ;

Simms, Lorinda ;

Shepherd, Frances A. .

ONCOLOGIST, 2009, 14 (03) :253-263

← 1 2 →